Back to top
more

Pieris Pharmaceuticals (PIRS)

(Real Time Quote from BATS)

$12.30 USD

12.30
90,663

+12.15 (8,371.07%)

Updated Apr 23, 2024 01:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PIRS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Pieris Pharmaceuticals, Inc. [PIRS]

Reports for Purchase

Showing records 1 - 20 ( 91 total )

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

01/03/2022

Company Report

Pages: 7

Dropping Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/02/2021

Company Report

Pages: 7

3Q21 Results; Pipeline Forges Ahead; Key Inflection Points Anticipated in Upcoming Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PIRS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/24/2021

Daily Note

Pages: 6

Preclinical Data Are an Intriguing Hint at What''s in Store for PRS-220''s Clinical Development

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

08/04/2021

Company Report

Pages: 8

2Q21 Results; Strategic Partnerships and Strong Financials Solidify Rich Pipeline Development

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

06/25/2021

Daily Note

Pages: 6

Introducing PRS-220; New Initiative in IPF Gets a Cash Jump Start

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

05/25/2021

Daily Note

Pages: 6

New Partnership, New Assets Coming; Pieris Continues to Deliver on Platform

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

05/17/2021

Company Report

Pages: 8

1Q21 Results; Many Hands Make Light Work, Multiple Partnerships Boost Clinical Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

04/26/2021

Daily Note

Pages: 6

Another Monday, Another Partnership

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

04/12/2021

Company Report

Pages: 9

Oncology Assets'' Profiles Continue to Strengthen

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

03/30/2021

Company Report

Pages: 7

2020 Results; PRS-060 Enters Phase 2a Trial; Important Updates at AACR

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

03/25/2021

Daily Note

Pages: 5

PRS-343 Reach Broadens; New Trial and Strategic Cash Received

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

01/19/2021

Daily Note

Pages: 4

Path Cleared for PRS-343; Looking Forward to Phase 2 Gastric Study

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

11/04/2020

Company Report

Pages: 8

3Q20 Results; Checking Important Boxes to Push Programs Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

09/21/2020

Company Report

Pages: 8

PRS-343 Continues Its Positive Push Forward

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

08/10/2020

Company Report

Pages: 6

2Q20 Results; Momentum Continues to Build Across Programs

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

07/21/2020

Daily Note

Pages: 4

PRS-343 Delivery to Be Tweaked; See Minor Impact to Timelines

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/11/2020

Company Report

Pages: 7

1Q20 Results; PRS-343 and PRS-060 Ready for Next Steps

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

03/24/2020

Daily Note

Pages: 4

Focus and Decisions out of Servier Partnership

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Pieris Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/12/2020

Company Report

Pages: 7

2019 Results; Important Boost in Visibility Expected in 2020 for PRS-060 and PRS-343

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party